RADIANT: A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas


Stem Cell / Bone Marrow Transplant : Relapsed or refractory solid tumors or lymphomas


This is a phase I study designed to determine the possibility of a new treatment using stem cell transplantation. This is a two-step process. It starts with giving chemotherapy medications to damage or kill the patient’s bone marrow. By damaging or killing the bone marrow, room is made within the bones-called the “bone marrow space.” The patient then gets stem cells from bone marrow of another person called the “donor.” Donor stem cells are needed in order to restore and “rebuild” the patient’s bone marrow that has been damaged from the chemotherapy and to help build healthy immune and blood cell forming systems.

Additionally, we intend to study blood cell recovery as well as infection rates and other complications. We expect that 12 transplant recipients will participate in the study over the next 3 years.



Transplant recipient


Transplant donor

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


David Shook, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Fax: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.